Psychedelics

Recent research shows psilocybin effectively reduces depression in cancer patients, with promising results in therapeutic settings.

FDA's groundbreaking guidance aims to advance psychedelic drug research and promote safety.

Transient functional brain changes with psilocybin therapy resemble the “brain reset” phenomenon and may serve as the putative predictors of psilocybin antidepressant response.

Randomized trials of psychedelics underutilize blind assessment, active drug controls, and testing psychological support against minimal-support conditions—elements that would improve quality or provide important information.

Colorado said yes to Proposition 122, which legalizes the medically supervised use of psilocybin.